Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, shares the findings of an exploratory analysis of the IMpower 133 trial (NCT02763579), aiming to assess the efficacy of atezolizumab maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC). The trial randomized over 400 patients to receive carboplatin+etoposide (CP/ET) with atezolizumab or placebo, followed by maintenance therapy with atezolizumab or placebo until unacceptable toxicity, disease progression, or loss of benefit. When assessing patients who reached the maintenance phase, atezolizumab maintenance therapy was shown to improve progression-free survival and overall survival compared to the placebo arm. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.

свернуть